Disruptive technologies in health care disenchanted: a systematic review of concepts and examples.

Biomedical Diffusion Disruptive technology Health care markets Innovation Systematic review Technology assessment

Journal

International journal of technology assessment in health care
ISSN: 1471-6348
Titre abrégé: Int J Technol Assess Health Care
Pays: England
ID NLM: 8508113

Informations de publication

Date de publication:
16 May 2022
Historique:
pubmed: 17 5 2022
medline: 30 8 2022
entrez: 16 5 2022
Statut: epublish

Résumé

To clarify the concept of disruptive technologies in health care, provide examples and consider implications of potentially disruptive technologies for health technology assessment (HTA). We conducted a systematic review of conceptual and empirical papers on healthcare technologies that are described as " Of 4,107 records, 28 were included in the review. Most of the papers included conceptual discussions and business models for disruptive technologies; only few papers presented empirical evidence. The majority of the evidence is related to the US healthcare system. Key arguments for describing a technology as disruptive include improvement of outcomes for patients, improved access to health care, reduction of costs and better affordability, shift in responsibilities between providers, and change in the organization of health care. A number of possible predictors for disruption were identified to distinguish these from " Since truly disruptive technologies could radically change technology uptake and may modify provision of care patterns or treatment paths, they require a thorough evaluation of the consequences of using these technologies, including economic and organizational impact assessment and careful monitoring.

Identifiants

pubmed: 35570673
doi: 10.1017/S0266462322000307
pii: S0266462322000307
doi:

Types de publication

Journal Article Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

e70

Auteurs

Matthias Perleth (M)

Abteilung Fachberatung Medizin, Gemeinsamer Bundesausschuss (G-BA), Berlin, Germany.

Rossella Di Bidino (R)

Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Directorate for Technology and Innovation, Health Technology Assessment Unit, Rome, Italy.

Li-Ying Huang (LY)

Division of Health Technology Assessment, Center for Drug Evaluation, Taipei, Taiwan.

Lydia Jones (L)

Abteilung Fachberatung Medizin, Gemeinsamer Bundesausschuss (G-BA), Berlin, Germany.

Michelle Mujoomdar (M)

Scientific Affairs, Canadian Agency for Drugs and Technologies in Health (CADTH), Ottawa, ON, Canada.

Susan Myles (S)

Health Technology Wales, Cardiff, United Kingdom.

Andres Pichon-Riviere (A)

Health Technology Assessment and Health Economics Department, Institute for Clinical Effectiveness and Health Policy, University of Buenos Aires, Buenos Aires, Argentina.

Junainah Sabirin (J)

Malaysian Health Technology Assessment Section (MaHTAS), Medical Development Division, Ministry of Health Malaysia, Putrajaya, Malaysia.

Tara Schuller (T)

International Network of Agencies for Health Technology Assessment (INAHTA) Secretariat, Edmonton, AB, Canada.

Jennifer Washington (J)

Health Technology Wales, Cardiff, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH